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   Summary & Conclusion 
Hereditary platelet function defects such as Bernard-Soulier syndrome (BSS) and 
Glanzmann thrombasthenia (GT) affect primary hemostasis and lead to bleeding diathesis. 
BSS is a recessively inherited hemorrhagic disorder caused by the quantitative or 
functional deficiency of one of the glycoproteins forming the GPIbα/Ibβ/IX/V complex. 
The platelet receptor for the von Willberand factor on the platelet surface, in patients 
affected by BSS platelet adhesion to the damaged vascular wall, is severely impaired but 
platelet aggregation and secondary hemostasis are normal (chapter 2.2).  
GT is a recessively inherited bleeding disorder that is caused by the quantitative or 
functional deficiency of integrin αIIbβ3 (or glycoprotein IIb/IIIa), which is the platelet 
fibrinogen  receptor (chapter 2.4). 
 
GT and BSS are extremely rare disorders. Our findings are remarkable for the high 
prevalence of GT and BSS relative to the general population of South Iran. Assuming that 
we were able to identify all the affected patients, an approximate prevalence of 1:200 000 
for GT  and 1:600 000 for BSS can be estimated (chapter 2.1). 
We reviewed the clinic and hospital records of 40 patients before and after referral to 
our specialized center in order to describe the natural history of these conditions in terms of 
bleeding symptoms and transfusion requirements (chapter 2.1). Twenty-three patients from 
16 different families were diagnosed with GT. Consanguinity among parents was present in 
all but one patient. Diagnosis was made in patients who had a normal platelet count, 
severely impaired platelet aggregation with high concentrations of ADP, collagen and 
arachidonic acid but normal aggregation with ristocetin. On flow cytometry, 19 patients 
were diagnosed type I GT (<5% of GpIIb/IIIa expression) and four type II GT (GpIIb/IIIa 
expression between 5% -20%). Median age at first symptoms was 2 years; >50% of patients 
were diagnosed because of epistaxis. 
BSS was diagnosed in seven individuals from four different families and all patients 
had consanguineous parents. Diagnosis was made on patients who had normal platelet 
aggregation to ADP, collagen and arachidonic acid but a severely defective response to 
large concentrations of ristocetin (1.5 mg/ml). Flow cytometry revealed that GpIb 
expression was <2%  in six cases compared with the expression in a control, in the 
remaining patient it was 12%. In these patients, platelet count was always low. When blood 
smears were analyzed macrothrombocytopenia was a constant feature. 
The morbidity associated with GT was significant, because two-thirds of patients came 
to our observation due to bleeding complications before the age of five and >80% of the 
patients with GT were transfused at least once to control bleeding. Moreover, in this group 
of patients the median hemoglobin level was 10.3 g/dl, probably indicative of the presence 
of unadverted chronic bleeding. The vast majority of GT patients were type I, only four 
patients being diagnosed with type II.  No patient had type III (chapter 2.1). 
 
BSS was associated with significant bleeding problems that required medical attention 
early in life, Median age at first symptom was 15 months; the most common presentations 
were post injection or post vaccination. Three patients had been transfused more than five 
times, two at least once, while the remaining two had not required platelet transfusion 
(chapter 2.1). 
In conclusion, we have reported the first complete laboratory-based investigation of a 
large cohort of South Iranian patients with GT or BSS, showing that both of these disorders 
are associated with significant bleeding diathesis (chapter 2.1). Earlier diagnosis of these 
patients would be helpful for their clinical management; therefore, these diagnoses should 
be aggressively sought in the offspring of consanguineous marriages presenting with a 
suggestive bleeding history. 
We sequenced the GPIb and GPIX genes of the seven BSS patients and of all the 
available first and second degree relatives, in order to identify the mutations causing BSS. 
The presence or the absence of bleeding symptoms, and GPIb/IX/V expression were 
investigated in heterozygous carriers identified through genotyping. In two of the three 
families analyzed we found a missense mutation (a GpIX Phe 55Ser substitution) 
previously described in two patients, one from Japan and one from The Netherlands 
(chapter 2.2). The mutation is located in the leucine-rich motif of GpIX, in an area that is 
critical for GpIX-GpIb association. It is well known that only if all the subunits of the 
glycoprotein complex associate in the  correct fashion can GpIb/IX/V be expressed on the 
plasma membrane of platelets. In one family we identified a previously undescribed 
cytosine insertion at position 3221 causing a frame shift of the entire GpIb alpha gene, and 
it is reasonable to expect that no protein is produced. Actually, no GpIb/IX/Vwas detected 
by flow cytometry on platelets of affected individuals. The second purpose of this study 
was to investigate, in terms of bleeding symptoms, platelet number, morphology and 
GpIb/IX/V surface expression carriers and normal individuals in the same families. 
No reduction in platelet count or signs of macrothrombocytopenia were found in two 
families carrying the same BSS mutation. In one family, a slight reduction in GpIb 
expression in heterozygous carriers was observed by flow cytometry, while in one family 
expression was above 75% in all individuals tested. The addition of the GpIb alpha 
nucleotide substitution GPIBA 3064 T>C ,a polymorphism known to enhance GpIb 
expression, probably contributes to normalize the complex expression in heterozygous 
carriers (chapter 2.2).  
Analyzing the mutations of Italian GT patients we found that a patient had a αIIb 
G236E missense substitution that substitutes glycine from the highly conserved motif of 
blade 4 of the β-propeller. In this study (chapter 2.4), the effects of a mutation causing GT 
were analyzed using flow cytometry, biochemistry and immunofluorescence. The mutation 
was chosen because it causes the loss of a predictably very important glycine from the αIIb-
β A propeller, since it is inserted between two rings of aromatic residues that stabilize the 
αIIb-β3 interface. Our hypothesis was that the mutation alters the association surface of the 
αIIb-β A propeller and destabilizes the complex with β3.  
We showed by flow cytometry analysis that transfected cells express at very low levels 
the mutant αIIbβ3 on their membrane, a finding compatible with the GT phenotype. 
We demonstrated that αIIbG236E is produced at levels comparable to those of normal 
αIIb, but several aspects of its maturation/association process are defective. The association 
with β3 in the endoplasmic reticulum is indeed hampered, and this is demonstrated by the 
presence of an increased amount of pro-αIIbG236E in transfected cells. Moreover, in 
Western blots from lysates of cells transfected with αIIbG236E, a band of low molecular 
weight reacting with antibodies against αIIb was identified, probably a sign of degradation 
of the uncoupled mutated protein. Even though a certain amount of the complex is formed 
and moves to the Golgi (as demonstrated by immunofluorescence studies) αIIbG236E and 
β3 appear to loosely associated, as shown by the inability of an anti-αIIb antibody to 
immunoprecipitate β3 in lysates from transfected cells. 
In the present study, we confirmed that a critical area for the αIIb-β3 association is the 
aromatic residues’ rings, and inserting residues that either alter charge or that are bulky 
interferes with the biogenesis of the receptor, thereby giving rise to GT (chapter 2.4). 
Factor X (FX) deficiency is a rare severe hemorrhagic condition inherited as an 
autosomal recessive trait. It is one of the most severe recessive inherited coagulation 
disorders. We analyzed the clinical manifestations, laboratory phenotype and genotype in 
10 patients with severe FX deficiency and in their heterozygous relatives (chapter 2.3). The 
most frequent bleeding episodes were hematomas (70%) and gum bleeding (60%). In all, 
50% of the homozygous patients required blood transfusion and one-third of heterozygotes 
required treatment after surgery or delivery. Homozygous candidate mutations were 
identified, and the genetic characterization revealed six different missense mutations, two of 
which were novel. The first mutation was p.Glu69Lys, consisting of a G to A transition 
(c.205G>A) in exon 2 encoding the Gla-domain, identified in an 11 years old boy. The 
vitamin K-dependent g-glutamyl carboxylase catalyzes the post-translational modification 
of specific glutamic acid residues to g-carboxyglutamic acid (Gla) residues in the Gla-
domain. 
 
The second novel mutation was p.Asp103His, identified in a 19 years old woman, 
consisting of a G to C transversion (c.307G>C) in exon 4 encoding the EGF1 domain. 
Correct post-translational modifications, such as g-carboxylation, glycosylation and b-
hydroxylation, are essential for the FX protein to be fully functional, because they may alter 
physical and chemical properties, including folding and thus protein stability (chapter 2.3 ). 
The b-hydroxylation site of FX is located in the first EGF domain at Asp103, resulting in a 
b-hydroxyaspartic acid. The replacement of histidine at this position will probably result in 
the loss of FX function by affecting b-hydroxylation and thereby causing a severe FX 
deficiency. The remaining four mutations had been reported and were all identified in the 
homozygous state. 
 
